| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Editorial |
1 Abramson Cancer Center, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; 2 National Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia; and 3 Fred Hutchinson Cancer Research Center, Seattle, Washington
Requests for reprints: Timothy Rebbeck, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021. Phone: 215-898-1793; Fax: 215-4409355. E-mail: trebbeck{at}cceb.med.upenn.edu
"A foolish consistency is the hobgoblin of little minds, adored by little statesmen and philosophers and divines."—Ralph Waldo Emerson
A goal of genetic association studies is to identify disease-causing genes. True positive associations between genetic variants and disease traits have the potential both to elucidate biologic principles and to lead to translation of research into clinical or preventive practice. For instance, an environmental effect on cancer risk may vary with genotype; or response to a treatment can differ based on information contained in the genotype. However, the reputation of genetic association studies has suffered because of the difficulty identifying reproducible and biologically interpretable results. Although criteria for identifying truly causative events in disease etiology have been proposed in numerous settings (1-7), we need to advance both conception and methods to improve the execution, interpretation, and integration of genetic association studies.
Studies on genetic associations in cancer have been published at an increasing pace. The CDC-curated published literature database on genetic associations (8) reveals the tremendous growth of this literature (Table 1 ). The annual number of reports of genetic associations involving cancer as an outcome has more than tripled over the past 6 years. These publications include an increasing number of articles on gene-gene and gene-environment interactions, as well as systematic reviews and meta-analyses that integrate the literature on genetic variants with that on cancer risk. This upward trend is likely to continue over the next few years, particularly with the advent of genome-wide association platforms in which hundreds of thousands of genetic variants will be studied simultaneously in large-scale consortium studies. So where is the field going? And how can CEBP help to bring order to this increasing flood of literature?
|
Nonetheless, many studies are replicated (9), and many unreplicated associations could ultimately have biological or clinical relevance. Thus, a simple-minded requirement for replicating studies of genetic associations is in danger of becoming the hobgoblin of human genetics research. Overemphasis on the apparent inconsistency of association-study results fails to acknowledge the complexity and heterogeneity that underlie all common diseases, including cancer. For example, an association may genuinely be present (or detectable) in some populations or subpopulations, but not others. An association may be observed only in a specific context (e.g., under exposure to a relevant agent), but such contexts are not always understood nor are the relevant exposures always well measured. Complexity and heterogeneity are always ignored in the design, analysis, execution, or interpretation of association studies. Most recognize how unlikely it is that a single nucleotide variant (no matter how functionally relevant) has a simple relationship with the risk of developing complex diseases (12). It is far more likely that many genetic variants, in conjunction with environmental exposures, will explain variation in disease etiology, drug response, and prognosis. A correlate of this higher-order complexity is that the marginal effects of single genetic variants may be obscured, and studies that do not properly account for this complexity are likely to miss relevant etiologic events. Therefore, studies need to be designed, executed, and interpreted in recognition of this complexity. A lack of consistency of associations may not always reflect an absence of causative association in disease but may instead be the consequence of true heterogeneity in the effects of genetic variants, exposures, or their interactions.
To avoid having overly simplistic notions of consistency overtake and hamper scientific progress, a sophisticated framework is required to identify biologically or clinically meaningful genetic associations. The Human Genome Epidemiology (HuGENet) Network4 and Cancer Epidemiology, Biomarkers & Prevention (CEBP) have provided separate forums for the publication, interpretation, and synthesis of association studies. Now CEBP and HuGENet will team up to make sense of this evolving field. CEBP has been a leader in publishing genetic association studies in cancer but recognizes the limitations of the literature in attempting to identify truly causative associations with biologic, clinical, or public health relevance. HuGENet is an open global collaboration of individuals and groups interested in advancing the integration of knowledge and applications of genetic information in medicine and public health. HuGENet sponsors methodologic workshops, hosts a published literature database, promotes systematic reviews of genetic associations-HuGE reviews (13), and convenes collaborations among consortia and networks through its "network of networks" (14). CEBP and HuGENet have individually and jointly proposed guidelines by which an improved environment for the publication of association studies can be achieved (2, 15-17). These guidelines encompass biological plausibility; population genetics structure (including factors related to race or ethnicity); appropriate laboratory and questionnaire measurements of exposures; consideration of etiologic complexity and heterogeneity; appropriate study design; and the correct inferential methods that consider etiologic complexity.
Current guidelines, however, remain inadequate and require further development. HuGENet serves as a focus for this effort and provides continuing guidance and direction for the field (18, 19). CEBP recognizes the merit of the structured approach that HuGENet can provide to evaluate association study results. CEBP therefore encourages the publication of methodological research that enhances the field of association studies, and applied association studies that appropriately consider etiologic complexity and replication, as well as meta-analyses that summarize the existing literature. CEBP further encourages authors interested in integrating information on genetic associations to use the HuGENet handbook for systematic reviews as a framework for providing meaningful information to the scientific literature (20). More than ever, as the pace of publication continues to increase, this field needs a collective effort to establish and apply the best set of guidelines for the analysis, interpretation, and synthesis of genetic associations.
 |
Footnotes |
|---|
4 http://www.cdc.gov/genomics/hugenet/default.htm 
Received 3/28/07; accepted 3/28/07.
|
References |
|---|
 Top References |
|---|
This article has been cited by other articles:
|
|
 |
|
  T. Hwang, H. Sicotte, Z. Tian, B. Wu, J.-P. Kocher, D. A. Wigle, V. Kumar, and R. Kuang Robust and efficient identification of biomarkers by classifying features on graphs Bioinformatics, September 15, 2008; 24(18): 2023 - 2029. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
